Brief: Regen BioPharma says cancer stem cell gene target key mediator of cancer immune surveillance
29/09/2015 13:30
Sept 29 (Reuters) - Regen BioPharma Inc RGBP.OB : * Cancer stem cell gene target shown to be a key mediator of cancer immune surveillance by independent researchers * Source text for Eikon ID:nPn2Ggp5j * Further company coverage RGBP.OB ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on Regen BioPharma
See all newsBrief: Regen Biopharma Prepares Response For FDA Regarding Its Orphan Drug Application For HemaXellerate
Brief: Regen Biopharma Expands Vision For Phase 1 Clinical Trial Of Hemaxellerate
Brief: Regen Biopharma, Inc. Receives First Phase Of Confirmatory Study
Brief: Regen Biopharma Files Provisional Patent On Car-T Cell Capable Of Attracting And Educating Naïve T Cells
Brief: Regen Biopharma addresses potential impact of recent Bristol Myers Squibb's $2.3 billion acquisition of IFM Therapeutics